Related Experiment Video

Updated: Jul 6, 2026

Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation
07:00

Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation

Published on: August 23, 2018

Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases

Cedo M Bagi1, Gregory W Roberts, Catharine J Andresen

  • 1Pfizer Inc., PGRD, World Wide Comparative Medicine, Groton, Connecticut 06340, USA. cedo.bagi@pfizer.com

Cancer
|March 19, 2008
PubMed
Abstract

Insights

PF-562,271 effectively treats lytic bone metastases by inhibiting tumor growth and restoring bone density. This novel therapy shows promise for cancer patients with bone metastases and osteoporosis.

Area of Science:

  • Oncology
  • Bone Biology
  • Pharmacology

Background:

  • Lytic bone metastases are a common and challenging complication in cancer patients.
  • Tumor cells, bone matrix, and bone cells interact to drive lytic bone metastases.
  • Focal adhesion kinase (FAK) and Pyk2 play roles in bone and cancer physiology.

Purpose of the Study:

  • To evaluate the efficacy of PF-562,271 in treating lytic bone metastases.
  • To assess the impact of PF-562,271 on tumor growth, bone resorption, and bone formation.

Main Methods:

  • MDA-MB-231 cells were implanted in rat tibiae to model lytic bone metastases.
  • PF-562,271 was administered orally at 5 mg/kg for 28 days.
  • Tumor progression, bone parameters, and osteoclast activity were monitored using various techniques.

Main Results:

  • PF-562,271 was well tolerated and increased osteocalcin and cancellous bone parameters.
  • PF-562,271 reduced tumor growth and promoted bone healing in tumor-bearing tibiae.
  • Osteoclast-mediated bone resorption was identified as the primary mechanism of bone loss.

Conclusions:

  • Oral PF-562,271 (5 mg/kg) suppressed intratibial tumor growth and local spread.
  • PF-562,271 effectively restored tumor-induced bone loss.
  • PF-562,271 offers a dual therapeutic approach for bone metastases and cancer-associated osteoporosis.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...